Search results
Results from the WOW.Com Content Network
Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma), [citation needed] diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors ().
An octreotide scan is a type of SPECT scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide , a drug similar to somatostatin , is radiolabeled with indium-111 , [ 1 ] and is injected into a vein and travels through the bloodstream.
Octreotate or octreotide acid is a somatostatin analogue that is closely related to octreotide. Its amino acid sequence is H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-OH while octreotide has the terminal threonine reduced to the corresponding amino alcohol.
The US Food and Drug Administration (FDA) approved 177 Lu dotatate based primarily on evidence from one clinical trial, NETTER-1 of 229 participants with somatostatin-receptor positive midgut GEP-NETs. [15] Enrolled participants had tumors which could not be surgically removed and were worsening while receiving treatment with octreotide. [15]
Edotreotide (USAN, also known as (DOTA 0-Phe 1-Tyr 3) octreotide, DOTA-TOC, DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer. [3] When used therapeutically it is an example of peptide receptor radionuclide therapy.
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin , like octreotide .
DOTA-TATE is a compound containing tyrosine 3-octreotate, [2] an SSR agonist, and the bifunctional chelator DOTA (tetraxetan). [5] [6] SSRs are found with high density in numerous malignancies, including CNS, breast, lung, and lymphatics. [7]
Somatrem was first marketed under the brand name Protropin by Genentech in 1985. [2] It differs from endogenous growth hormone by the addition of an extra methionine at the N-terminus [3] [circular reference]. Somatrem has largely been replaced by somatropin, marketed by several companies including by Genentech as the brand Nutropin.